Singapore markets closed

Straits Times Index
3,110.73
+36.47(+1.19%)
Nikkei
32,307.86
-550.45(-1.68%)
Hang Seng
16,334.37
-11.52(-0.07%)
FTSE 100
7,554.47
+40.75(+0.54%)
Bitcoin USD
44,327.55
+863.07(+1.99%)
CMC Crypto 200
914.81
+18.10(+2.02%)

Repare Therapeutics Inc. (RPTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD

Add to watchlist

6.35

+0.60

(+10.43%)

At close: 04:00PM EST

6.69

+0.34

(+5.35%)

After hours:

05:18PM EST

Trade prices are not sourced from all markets

Press Releases

Business Wire
Repare Therapeutics Unveils Two Programs Expected to Enter Clinical Trials in 2024: RP-1664, an Oral PLK4 Inhibitor, and RP-3467, an Oral Polθ Inhibitor
CAMBRIDGE, Mass. & MONTREAL, November 15, 2023--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today disclosed polo-like kinase 4 (PLK4) as the target of its RP-1664 development program and reported comprehensive preclinical data for both RP-1664 and the Company’s Polθ inhibitor, RP-3467.
Business Wire
Repare Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
CAMBRIDGE, Mass. & MONTREAL, November 09, 2023--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the third quarter ended September 30, 2023.
Business Wire
Repare Therapeutics to Host Investor and Analyst Conference Call and Webcast
CAMBRIDGE, Mass. & MONTREAL, November 07, 2023--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced it will host a conference call and live webcast to present the latest data from its ongoing preclinical programs, RP-1664 and RP-3467, a newly designated Polθ inhibitor, on Wednesday, November 15, 2023 at 8:00 a.m. Eastern Time.